An observational study in Metastatic Hormone-Sensitive Prostate Cancer, sponsored by Bayer. Recruiting at 16 sites in 16 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Prostatic Neoplasms by Bayer — 11 open to participants now, 16 under way, 1 of them phase 3. Prostatic Neoplasms · Bayer.
Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 8th largest by planned enrollment of the 40 observational ones that give a count, is one of 6 that started in 2026, is one of 40 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 70th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →11 of the 75 studies in Prostatic Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in China
Ages 18+ · Men only
Bayer · Sites in United States
Ages 55+ · Men only
Bayer · Sites in China
Ages 18+ · Men only
Bayer · Sites in Germany
Ages 18+ · Men only
Bayer · Sites in Australia
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 14 · Phase 3 8 · Phase 4 2
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 82 across the 34 interventional studies, 700 across the 40 observational. Of the 57 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
4 of the studies in Prostatic Neoplasms by Bayer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
| NCT07223372BayerAn Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia | 2026-11-30 |
| NCT07672119BayerA Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide | 2027-04-29 |
| NCT06052306BayerA Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | 2027-06-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Prostatic Neoplasms by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an international, prospective, open-label, multicenter, multi-cohort, non-interventional observational study designed to describe the real-world effectiveness and safety of darolutamide in combination with androgen deprivation therapy (ADT), with or without docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aims to enroll approximately 1,600 male patients (800 per cohort) from multiple countries, primarily in Europe, who have a diagnosis of mHSPC and for whom a decision to treat with darolutamide has been made by the treating physician prior to enrollment. The primary objective is to estimate the proportion of patients achieving undetectable prostate-specific antigen (PSA) levels (\<0.2 ng/mL) at 1 year of treatment in each cohort. Secondary objectives include describing patient demographics, clinical characteristics, prior and concomitant treatments, adverse events, and clinical effectiveness measures such as overall survival, time to new treatment, time to castration resistance, and time to PSA progression. Further objectives involve assessing quality of life, reasons for not adding docetaxel, outcomes by patient subgroups (e.g., Gleason score, disease volume, ECOG status), genomic testing results, and hospitalization rates. Data will be collected using electronic case report forms (eCRF) during routine clinical practice, with no additional diagnostic or monitoring procedures required beyond standard care. All patients must provide informed consent prior to participation. The study will comply with applicable regulatory requirements, including IEC/IRB approval in all participating countries. Statistical analyses will be descriptive and exploratory, with interim analyses planned after 200, 400, and 600 patients per cohort have completed at least 12 months of treatment or discontinued therapy. The study is expected to provide valuable insights into the real-world use of darolutamide in mHSPC, supporting clinical decision-making and enhancing understanding of treatment patterns, effectiveness, and safety in diverse patient populations.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Male patients with a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) for whom a decision to treat with darolutamide has been made by the treating physician prior to enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group includes men with metastatic hormone-sensitive prostate cancer (mHSPC) who are treated with a combination of darolutamide, androgen deprivation therapy (ADT), and docetaxel. The decision to use this triplet therapy is made by the treating physician as part of routine clinical practice before the patient enrolls in the study. Patients in this cohort receive all three treatments according to local standard of care.
Drug: Darolutamide (BAY 1841788) · Drug: ADT · Drug: Docetaxel
This group includes men with metastatic hormone-sensitive prostate cancer (mHSPC) who are treated with darolutamide and androgen deprivation therapy (ADT), but without docetaxel. The decision to use this doublet therapy is made by the treating physician as part of routine clinical practice before the patient enrolls in the study. Patients in this cohort receive darolutamide and ADT according to local standard of care.
Drug: Darolutamide (BAY 1841788) · Drug: ADT
Darolutamide administered per local standard of care in combination with ADT.
Also known as: NUBEQA
Androgen deprivation therapy administered per local standard of care.
Docetaxel administered per local standard of care in combination with darolutamide and ADT for cohort 1.
Proportion of patients in cohort 1 achieving undetectable PSA (<0.2 ng/mL) at 1 year
To describe the effectiveness of darolutamide + ADT + docetaxel in patients with mHSPC by means of estimating the prostate-specific antigen (PSA) undetectable rates (PSA\<0.2 ng/mL) after 1 year of study treatment.
Time frame: after 1 year of treatment
Proportion of patients in cohort 2 achieving undetectable PSA (<0.2 ng/mL) at 1 year
To describe the effectiveness of darolutamide + ADT in patients with mHSPC by means of estimating the prostate-specific antigen (PSA) undetectable rates (PSA\<0.2 ng/mL) after 1 year of study treatment.
Time frame: after 1 year of treatment
Overall survival per cohort and per country
Time from start of darolutamide treatment until death from any cause.
Time frame: up to 4 years
Overall survival per cohort in all countries
Time from start of darolutamide treatment until death from any cause.
Time frame: up to 4 years
Time to subsequent treatment per cohort and per country
Time from start of darolutamide treatment to initiation of a new anti-cancer therapy.
Time frame: up to 4 years
Time to subsequent treatment per cohort in all countries
Time from start of darolutamide treatment to initiation of a new anti-cancer therapy.
Time frame: up to 4 years
Time to castration resistance (CRPC) per cohort and per country
Time from enrollment until documented clinical or PSA progression with testosterone level \<50 ng/dL or documented medical/surgical castration.
Time frame: up to 4 years
Time to castration resistance (CRPC) per cohort in all countries
Time from enrollment until documented clinical or PSA progression with testosterone level \<50 ng/dL or documented medical/surgical castration.
Time frame: up to 4 years
Time to PSA progression per cohort and per country
Time from start of darolutamide treatment to PSA progression (≥25% increase above nadir and ≥2 ng/mL, confirmed by a second value ≥3 weeks later, but prior to 6 months, while on treatment).
Time frame: up to 4 years
Time to PSA progression per cohort in all countries
Time from start of darolutamide treatment to PSA progression (≥25% increase above nadir and ≥2 ng/mL, confirmed by a second value ≥3 weeks later, but prior to 6 months, while on treatment).
Time frame: up to 4 years
PSA response rate per cohort and per country
Proportion of patients with blood PSA level \<0.2 ng/mL, confirmed by a second subsequent PSA value \<0.2 ng/mL 3 or more weeks later
Time frame: 1 year
PSA response rate per cohort in all countries
Proportion of patients with blood PSA level \<0.2 ng/mL, confirmed by a second subsequent PSA value \<0.2 ng/mL 3 or more weeks later
Time frame: 1 year
Survival rate per cohort and per country
Survival rate at specified time points.
Time frame: up to 4 years
Survival rate per cohort and all countries
Survival rate at specified time points.
Time frame: up to 4 years
Time to discontinuation per cohort and per country
Time from start of darolutamide treatment to permanent discontinuation or death
Time frame: up to 4 years
Time to discontinuation per cohort in all countries
Time from start of darolutamide treatment to permanent discontinuation or death
Time frame: up to 4 years
Reason for discontinuation percohort and per country
Reason for permanent darolutamide discontinuation
Time frame: up to 4 years
Reason for discontinuation per cohort in all countries
Reason for permanent darolutamide discontinuation
Time frame: up to 4 years
Patient demographics per cohort and per country
Demographic characteristics at the first documented regular visit ion the study, referred to as baseline).
Time frame: at baseline
Patient demographics per cohort in all countries
Demographic characteristics at the first documented regular visit ion the study, referred to as baseline).
Time frame: at baseline
Medical History per cohort and per country
The medical history will be documented at study start.
Time frame: at baseline
Medical History per cohort in all countries
The medical history will be documented at study start.
Time frame: at baseline
Concomitant medication per cohort and per country
Documentation of Concomitant medication.
Time frame: up to 4 years
Concomitant medication per cohort in all countries
Documentation of Concomitant medication.
Time frame: up to 4 years
Concomitant treatment per cohort and per country
Documentation of Concomitant treatments.
Time frame: up to 4 years
Concomitant treatment per cohort in all countries
Documentation of Concomitant treatments.
Time frame: up to 4 years
Darolutamide use per cohort and per country
To describe real-world use of darolutamide in mHSPC patients.
Time frame: up to 4 years
Darolutamide use per cohort in all countries
To describe real-world use of darolutamide in mHSPC patients.
Time frame: up to 4 years
Diagnostic Imaging Technology per cohort and per country
Documentation of Diagnostic Imaging Technology at the initial study visits (baseline).
Time frame: at baseline
Diagnostic Imaging Technology per cohort in all countries
Documentation of Diagnostic Imaging Technology at the initial study visits (baseline).
Time frame: at baseline
Adverse events per cohort and per country
Number of all adverse events.
Time frame: up to 4 years
Adverse events per cohort in all countries
Number of all adverse events.
Time frame: up to 4 years
Serious Adverse events per cohort and per country
Number of all serious adverse events.
Time frame: up to 4 years
Serious Adverse events per cohort in all countries
Number of all serious adverse events.
Time frame: up to 4 years
Drug-related Adverse events per cohort and per country
Number of all drug-related (darolutamide) adverse events.
Time frame: up to 4 years
Drug-related Adverse events per cohort in all countries
Number of all drug-related (darolutamide) adverse events.
Time frame: up to 4 years
Serious Drug-related Adverse events per cohort and per country
Number of all serious drug-related (darolutamide) adverse events.
Time frame: up to 4 years
Serious Drug-related Adverse events per cohort in all countries
Number of all serious drug-related (darolutamide) adverse events.
Time frame: up to 4 years
Adverse events leading to treatment discontinuation per cohort and per country
Number of adverse events leading to treatment discontinuation.
Time frame: up to 4 years
Adverse events leading to treatment discontinuation per cohort in all countries
Number of adverse events leading to treatment discontinuation.
Time frame: up to 4 years
Vital Signs: Blood Pressure per cohort and per country
Blood Pressure is measured in mmHg throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Blood Pressure per cohort in all countries
Blood Pressure is measured in mmHg throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Body Temperature per cohort and per country
Body Temperature is measured in degrees Celsius (°C) or Fahrenheit (°F) (as per local practice) throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Body Temperature per cohort in all countries
Body Temperature is measured in degrees Celsius (°C) or Fahrenheit (°F) (as per local practice) throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Weight per cohort and per country
Weight is measured in kilograms (kg) throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Weight per cohort in all countries
Weight is measured in kilograms (kg) throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Height per cohort and per country
Height is measured in centimeters (cm) throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Vital Signs: Height per cohort in all countries
Height is measured in centimeters (cm) throughout the study, at all major visit types, over the full observation period.
Time frame: up to 4 years
Laboratory Parameters: Hematology (Hemoglobin) per cohort and per country
Hemoglobin (g/dL)) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Hematology (Hemoglobin) per cohort in all countries
Hemoglobin (g/dL)) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Hematology (WBC) per cohort and per country
White Blood Cell Count (WBC) (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Hematology (WBC) per cohort in all countries
White Blood Cell Count (WBC) (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Hematology (Platelet Count) per cohort and per country
Platelet Count (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Hematology (Platelet Count) per cohort in all countries
Platelet Count (x10\^9/L) is performed throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (Creatinine) per cohort and per country
Serum Creatinine (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (Creatinine) per cohort in all countries
Serum Creatinine (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (ALT) per cohort and per country
Alanine Aminotransferase (ALT) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (ALT) per cohort in all countries
Alanine Aminotransferase (ALT) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (AST) per cohort and per country
Aspartate Aminotransferase (AST) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (AST) per cohort in all countries
Aspartate Aminotransferase (AST) (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (Bilirubin) per cohort and per country
Total Bilirubin (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (Bilirubin) per cohort in all countries
Total Bilirubin (mg/dL or µmol/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (Alkaline Phosphatase) per cohort and per country
Alkaline Phosphatase (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (Alkaline Phosphatase) per cohort in all countries
Alkaline Phosphatase (U/L) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (PSA) per cohort and per country
Prostate-Specific Antigen (PSA) (ng/mL) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Laboratory Parameters: Clinical Chemistry (PSA) per cohort in all countries
Prostate-Specific Antigen (PSA) (ng/mL) is determined throughout the study, at all major visit types, for the duration of darolutamide treatment and as needed during follow-up, up to the end of observation.
Time frame: up to 4 years
Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.
Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 47 months is close to that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.